「11C」JNJ54173717:一种新型P2X7受体放射性配体作为神经炎症标志物——人体生物分布、剂量学、脑动力学建模及帕金森病患者与健康志愿者脑内P2X7受体定量
本研究首次在人体中评估选择性P2X7受体示踪剂「11C」JNJ717,在健康志愿者和帕金森病患者中进行全身PET/CT生物分布与剂量学、90分钟动态PET/MR动力学建模及短期重测变异分析。结果显示该示踪剂安全,可逆双组织室模型最合适,健康志愿者与帕金森病患者平均VT无显著差异,但发现rs3751143基因型可能影响VT,重测变异平均10-15%。
要点
- 「11C」JNJ717安全,平均有效剂量4.47±0.32 μSv/MBq,最高吸收剂量在胆囊、肝脏和小肠。
- 可逆双组织室模型最合适,健康志愿者平均VT为3.4±0.8,帕金森病患者为3.3±0.7,组间无显著差异。
- 平均重测变异10-15%,VT时间稳定性允许扫描时间缩短至70分钟,基因型rs3751143可能影响VT。
核心结论
- 「11C」JNJ717安全且适用于定量人脑P2X7受体表达。
- 本初步研究中健康志愿者与帕金森病患者P2X7受体结合无显著差异。
- 结果提示未来P2X7受体PET分析需纳入基因型效应。
研究设计与样本
- 首次人体研究,包括3名健康志愿者(平均年龄30±2岁,2名女性)的全身PET/CT生物分布与辐射剂量学研究。
- 11名健康志愿者(平均年龄62±10岁,6名女性)和10名帕金森病患者(平均年龄64±8岁,3名女性;平均UPDRS运动评分21±8)接受90分钟动态同步PET/MR扫描以确定最适动力学模型。
- 7名受试者(平均年龄60±13岁,4名健康志愿者,1名女性)接受重测扫描。
- 对所有参与第二部分研究的受试者进行P2X7R的13个外显子基因分型。
- 进行组分析比较帕金森病患者与健康志愿者。
主要发现
- 平均有效剂量为4.47±0.32 μSv/MBq,最高吸收剂量位于胆囊、肝脏和小肠。
- 可逆双组织室模型是最合适的动力学模型,灰质和白质中VT值相对均匀。
- 健康志愿者平均VT为3.4±0.8,帕金森病患者为3.3±0.7,组间无显著差异。
- 发现可能的基因型效应(rs3751143)可影响VT。
- 平均重测变异为10-15%,VT时间稳定性允许扫描时间缩短至70分钟。
关键数值与推荐
- 平均有效剂量4.47±0.32 μSv/MBq。
- 健康志愿者平均VT为3.4±0.8,帕金森病患者为3.3±0.7,组间无显著差异。
- 平均重测变异10-15%。
- VT时间稳定性允许扫描时间缩短至70分钟。
- 基因型rs3751143可能影响VT。
临床怎么用
- 「11C」JNJ717可用于人脑P2X7受体表达的定量评估。
- 可采用可逆双组织室模型计算VT,扫描时间可缩短至70分钟。
- 未来P2X7R PET分析中应考虑基因型rs3751143的影响。
局限性
- 本研究为初步研究,样本量较小。
- 健康志愿者与帕金森病患者间P2X7R结合无显著差异,需进一步研究验证。
- 基因型效应需在未來研究中纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The P2X7 receptor (P2X7R) is an ATP-gated ion channel predominantly expressed on activated microglia and is important in neurodegenerative diseases including Parkinson's disease (PD). In this first-in-human study, we investigated [11C]JNJ54173717 ([11C]JNJ717), a selective P2X7R tracer, in healthy volunteers (HV) and PD patients. Biodistribution, dosimetry, kinetic modelling and short-term test-retest variation (TRV), as well as possible genotype effects, were investigated. METHODS: Biodistribution and radiation dosimetry studies were performed in three HV (mean age 30 ± 2 years, two women) using whole-body PET/CT. The most appropriate kinetic model was determined in 11 HV (mean age 62 ± 10 years, six women) and 10 PD patients (mean age 64 ± 8 years, three women; mean UPDRS motor score 21 ± 8) using 90-min dynamic simultaneous PET/MR scans. The total volume of distribution (VT) was calculated using a one-tissue and a two-tissue compartment model (1TCM, 2TCM) and Logan graphical analysis, and its time stability was assessed. Seven subjects underwent retest scans (mean age 60 ± 13 years, four HV, one woman). A group analysis was performed to compare PD patients and HV. Finally, 13 exons of P2X7R were genotyped in all subjects included in the second part of the study. RESULTS: The mean effective dose was 4.47 ± 0.32 μSv/MBq, with the highest absorbed doses to the gallbladder, liver and small intestine. A reversible 2TCM was the most appropriate kinetic model with relatively homogeneous VT values in the grey and white matter. Average VT values were 3.4 ± 0.8 in HV and 3.3 ± 0.7 in PD patients, with no significant difference between the groups, but a possible genotype effect (rs3751143) was identified which can affect VT. Average TRV was 10-15%. The stability of VT over time allowed a reduction in scan time to 70 min. CONCLUSION: [11C]JNJ717 is safe and suitable for quantifying P2X7R expression in human brain. In this pilot study, no significant differences in P2X7R binding were found between HV and PD patients. The results also suggest that genotype effects need to be incorporated in future P2X7R PET analyses.
引用
- Van Weehaeghe D, Koole M, Schmidt ME, et al. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019. PMID: 31243495. doi:10.1007/s00259-019-04369-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。